<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03474263</url>
  </required_header>
  <id_info>
    <org_study_id>ALS02</org_study_id>
    <nct_id>NCT03474263</nct_id>
  </id_info>
  <brief_title>IC14 for Rapidly Progressive Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <official_title>A Phase 2a, Open-Label Biomarker Study of IC14 for the Treatment of Patients With</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Implicit Bioscience</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Implicit Bioscience</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with rapidly progressive ALS will be assigned to IC14 intravenously on Day 1-4. This&#xD;
      4-day course will be repeated on Days 8-11. Patients will all undergo MR-PET scans at two&#xD;
      time points: before treatment onset and after the last treatment cycle. This scan will&#xD;
      measure areas of ALS disease activity and assess response to IC14 treatment. MR-PET scans&#xD;
      will be compared to historical controls.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, biomarkers-driven study.&#xD;
&#xD;
      Patients with rapidly progressive ALS will be assigned to the following dose regimen of IC14:&#xD;
&#xD;
      • 4 mg/kg intravenously on Day 1, followed by 2 mg/kg daily x 3 days on Days 2-4. This 4-day&#xD;
      course will be repeated on Days 8-11.&#xD;
&#xD;
      Patients will be followed for 28 days after the last dose of study drug. Patients will all&#xD;
      undergo [11C]-PBR28-MR-PET scans at two time points: before treatment onset and after the&#xD;
      last treatment cycle.&#xD;
&#xD;
      Patients will be followed for 28 days after the last dose of study drug for safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    seeking research grant support&#xD;
  </why_stopped>
  <start_date type="Anticipated">September 1, 2019</start_date>
  <completion_date type="Anticipated">July 12, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 12, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label Biomarkers-Driven Study Historical controls</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glial Activation</measure>
    <time_frame>one month</time_frame>
    <description>Glial activation measured in the motor region measured by [11C]-PBR28 positron emission tomography (PET). Studies have shown this marker localizes to areas of glial activation and correlates with disease progression and outcomes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum neurofilament</measure>
    <time_frame>one month</time_frame>
    <description>Serum neurofilament is a biomarker that has been shown to correlate with ALS severity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary p75 neurotrophin receptor</measure>
    <time_frame>one month</time_frame>
    <description>Urinary p75 neurotrophin receptor is a biomarker that has been shown to correlate with ALS severity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (Safety, Tolerability)</measure>
    <time_frame>six weeks</time_frame>
    <description>Adverse event reporting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>six weeks</time_frame>
    <description>Human anti-monoclonal antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration of IC14</measure>
    <time_frame>one month</time_frame>
    <description>Peak Plasma Concentration (Cmax) of IC14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>one month</time_frame>
    <description>Monocyte CD14 saturation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>IC14 (monoclonal anti-CD14 antibody)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biologic: IC14 (monoclonal anti-CD14 antibody) 4 mg/kg intravenously followed by IC14 2 mg/kg intravenously on Days 2-4. This four-day cycle will be repeated on Days 8-11.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biologic: IC14 (monoclonal antibody against human CD14)</intervention_name>
    <description>IC14 intravenous infusion daily for four days on two successive weeks then MR-PET Scan evaluation for impact on glial activation.</description>
    <arm_group_label>IC14 (monoclonal anti-CD14 antibody)</arm_group_label>
    <other_name>Anti-CD14</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Capable of providing informed consent and informed consent form signed prior to&#xD;
             initiation of any study-specific procedures.&#xD;
&#xD;
          2. Familial or sporadic ALS defined as clinically possible, probable, or definite by El&#xD;
             Escorial Criteria.&#xD;
&#xD;
          3. Rapidly progressive ALS defined by the Revised ALS Functional Rating Scale (ALSFRS-R)&#xD;
             slope ≥1 (48 minus ALSFRS-R score at screening / disease duration in months ≥ 1).&#xD;
&#xD;
          4. Upper Motor Neuron Burden Score of ≥ 25 (out of 45) at screening&#xD;
&#xD;
          5. First symptoms of ALS within 3 years of the screening visit&#xD;
&#xD;
          6. Age between 18 and 80 years at the time of the screening visit.&#xD;
&#xD;
          7. Not taking riluzole or edaravone or on a stable dose of riluzole or edaravone for at&#xD;
             least 3 months prior to screening visit.&#xD;
&#xD;
          8. Adequate bone marrow reserve, renal and liver function:&#xD;
&#xD;
               1. absolute neutrophil count ≥ 1500/µL&#xD;
&#xD;
               2. lymphocyte count &lt; 6000/µL&#xD;
&#xD;
               3. platelet count ≥ 150,000/µL&#xD;
&#xD;
               4. hemoglobin ≥ 11 g/dL&#xD;
&#xD;
               5. creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
               6. alanine transaminase (ALT) and/or aspartate transaminase (AST) ≤ 3x upper limits&#xD;
                  of normal (ULN)&#xD;
&#xD;
               7. total bilirubin ≤ 1.5x ULN&#xD;
&#xD;
               8. serum albumin ≥ 2.8 g/dL&#xD;
&#xD;
          9. Females of childbearing potential should be using and committed to continue using one&#xD;
             of the following acceptable birth control methods:&#xD;
&#xD;
               1. Sexual abstinence (inactivity) for 1 month prior to screening through study&#xD;
                  completion; or&#xD;
&#xD;
               2. Intrauterine device (IUD) in place for at least 3 months prior to study through&#xD;
                  study completion; or&#xD;
&#xD;
               3. Stable hormonal contraception for at least 3 months prior to study through study&#xD;
                  completion; or&#xD;
&#xD;
               4. Surgical sterilization (vasectomy) of male partner at least 6 months prior to&#xD;
                  study.&#xD;
&#xD;
         10. To be considered of non-childbearing potential, females should be surgically&#xD;
             sterilized (bilateral tubal ligation, hysterectomy, or bilateral oophorectomy at least&#xD;
             2 months prior to study) or be post-menopausal and at least 3 years since last menses.&#xD;
&#xD;
         11. Males with female partners of childbearing potential must use contraception through&#xD;
             study completion.&#xD;
&#xD;
         12. Ability to safely lie flat for 90 min for magnetic resonance-positron emission&#xD;
             tomography (MR-PET) procedures in the opinion of the Investigator.&#xD;
&#xD;
         13. Patients must also have a genotype associated with a high or mixed affinity&#xD;
             translocator protein (TSPO) (Ala/Ala or Ala/Thr) and ability to safely undergo MR-PET&#xD;
             scans based on the opinion of the Investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Dependence on invasive or non-invasive ventilation, defined as being unable to lay&#xD;
             supine without it, unable to sleep without it, or continuous daytime use; presence of&#xD;
             tracheostomy at screening; or presence of diaphragm pacing system at screening.&#xD;
&#xD;
          2. Exposure to any experimental treatment for ALS within the last 30 days or five&#xD;
             half-lives, whichever is longer.&#xD;
&#xD;
          3. Treatment within 12 months with immunomodulator or immunosuppressant agent (including&#xD;
             but not limited to cyclophosphamide, cyclosporine, interferon-α, interferon-β-1a,&#xD;
             rituximab, alemtuzumab, azathioprine, etanercept, infliximab, adalimumab,&#xD;
             certolizumab, golimumab, anakinra, rilonacept, secukinumab, tocilizumab, mycophenolate&#xD;
             mofetil, methotrexate, cell-depleting agents, total lymphoid irradiation, dimethyl&#xD;
             fumarate). Treatment with intravenous immunoglobulin (IVIG) within 2 months.&#xD;
             Non-steroidal anti-inflammatory drugs (NSAIDs) are acceptable.&#xD;
&#xD;
          4. Exposure at any time to any cell or gene therapies under investigation for the&#xD;
             treatment of ALS.&#xD;
&#xD;
          5. Known active current or history of recurrent bacterial, viral, fungal, mycobacterial&#xD;
             or other opportunistic infections; or major episode of infection requiring&#xD;
             hospitalization or treatment with intravenous (IV) antibiotics within 4 weeks.&#xD;
&#xD;
          6. Live-attenuated vaccines within 30 days before dosing. Subjects must agree to forego&#xD;
             live-attenuated vaccines throughout the study, including 60 days after the last dose&#xD;
             of study drug.&#xD;
&#xD;
          7. History of severe allergic or anaphylactic reactions to human, humanized or murine&#xD;
             monoclonal antibodies.&#xD;
&#xD;
          8. History of one or more of the following: cardiac insufficiency (New York Heart&#xD;
             Association [NYHA] III/IV), uncontrolled cardiac arrhythmias, unstable ischemic heart&#xD;
             disease, or uncontrolled hypertension (systolic blood pressure &gt; 170 mmHg or diastolic&#xD;
             blood pressure &gt; 110 mmHg).&#xD;
&#xD;
          9. History of myocardial infarction, or cerebrovascular accident.&#xD;
&#xD;
         10. Unstable pulmonary, renal, hepatic, endocrine or hematologic disease.&#xD;
&#xD;
         11. Autoimmune disease, mixed connective tissue disease, scleroderma, polymyositis, or&#xD;
             significant systemic involvement secondary to rheumatoid arthritis.&#xD;
&#xD;
         12. Evidence of active malignant disease, malignancies diagnosed within the previous 5&#xD;
             years, or breast cancer diagnosed within the previous 5 years (except skin cancers&#xD;
             other than melanoma).&#xD;
&#xD;
         13. History of human immunodeficiency virus infection or other immunodeficiency illness.&#xD;
&#xD;
         14. Unstable psychiatric illness defined as psychosis or untreated major depression within&#xD;
             90 days.&#xD;
&#xD;
         15. History of drug abuse (not including marijuana use) or alcoholism within the past 12&#xD;
             months.&#xD;
&#xD;
         16. Significant neuromuscular disease other than ALS.&#xD;
&#xD;
         17. Other ongoing disease that may cause neuropathy, such as toxin exposure, dietary&#xD;
             deficiency, uncontrolled diabetes, hyperthyroidism, cancer, systemic lupus&#xD;
             erythematosus or other connective diseases, infection with HIV, hepatitis B virus&#xD;
             (HBV), or hepatitis C (HCV), Lyme disease, multiple myeloma, Waldenström's&#xD;
             macroglobulinemia, amyloid, and hereditary neuropathy.&#xD;
&#xD;
         18. Pregnancy or breastfeeding.&#xD;
&#xD;
         19. Deprivation of freedom by administrative or court order.&#xD;
&#xD;
         20. Any contraindication to undergo magnetic resonance imaging (MRI) studies such as&#xD;
             history of a cardiac pacemaker or pacemaker wires; metallic particles in the body;&#xD;
             vascular clips in the head; prosthetic heart valves; or severe claustrophobia.&#xD;
&#xD;
         21. Unwilling or unable to discontinue benzodiazepine usage [other than lorazepam&#xD;
             (Ativan®), clonazepam (Klonopin®), or zolpidem (Ambien®)] for one day prior to and&#xD;
             during scanning.&#xD;
&#xD;
         22. Research imaging-related radiation exposure exceeds current institutional Radiology&#xD;
             Department guidelines&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Agosti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Implicit Bioscience Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Brisbane &amp; Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 9, 2018</study_first_submitted>
  <study_first_submitted_qc>March 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2018</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Motor Neurone Disease (MND)</keyword>
  <keyword>Amyotrophic Lateral Sclerosis (ALS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

